Detalle Publicación

ARTÍCULO

Circulating levels of the interferon-gamma-regulated chemokines CXCL10/CXCL11, IL-6 and HGF predict outcome in metastatic renal cell carcinoma patients treated with antiangiogenic therapy

Autores: Esteban, E.; Expósito Rincón, Francisco; Crespo, G.; Lambea, J.; Pinto, Á.; Puente, J.; Arranz, J. A.; Redrado Jordán, Miriam; Rodríguez-Antona, C.; De Andrea, Carlos Eduardo; López Brea, M.; Redín Cabodevilla, María Esther; Rodríguez, Á.; Serrano Tejero, Diego; García, J.; Grande, E.; Castellano, D.; Calvo González, Alfonso (Autor de correspondencia)
Título de la revista: CANCERS
ISSN: 2072-6694
Volumen: 13
Número: 11
Páginas: 2849
Fecha de publicación: 2021
Resumen:
We have studied blood levels of cytokines/chemokines in patients with metastatic renal cell carcinoma treated with sunitinib or pazopanib, with the goal of identifying biomarkers that can predict efficacy and survival. We have found that high levels of CXCL10, CXCL11, HGF and IL-6 before treatment associate with poor prognosis in these patients. Moreover, these factors are correlated in patients with renal carcinoma, suggesting a coordinated expression and secretion. We have developed a prognostic signature including these factors that predicts very accurately prognosis. Our results may help defining better the group of renal cell carcinoma patients who may benefit from sunitinib/pazopanib.
DOI: https://doi.org/10.3390/cancers13112849
Impacto:
Google Scholar